<br>Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance</br><em> – by Matthew E. Levison</em>

Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance – by Matthew E. Levison

26 April 2021
<br>Causes of antibiotic shortages and the solutions to address them</br><em> – by Enrico Baraldi</em>

Causes of antibiotic shortages and the solutions to address them – by Enrico Baraldi

10 February 2021
<br>Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment</br><em> – by Abiola Isawumi and Lydia Mosi</em>

Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment – by Abiola Isawumi and Lydia Mosi

18 January 2021
<br>Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities</br><em> – by Rachael Osagie</em>

Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities – by Rachael Osagie

9 December 2020
<br>The antibiotic R&D landscape in Japan</br><em> – by Norio Ohmagari</em>

The antibiotic R&D landscape in Japan – by Norio Ohmagari

25 November 2020
<br>Tackling the drug-resistance pandemic – 2020 and beyond</br><em> – by Laura J.V. Piddock</em>

Tackling the drug-resistance pandemic – 2020 and beyond – by Laura J.V. Piddock

23 November 2020
<br>Why are new antibacterials failing as commercial products?</br><em> – by Patricia A. Bradford</em>

Why are new antibacterials failing as commercial products? – by Patricia A. Bradford

19 November 2020
<br>COVID-19: Coinfection, secondary bacterial infections and AMR in India</br><em> – by Venkatasubramanian Ramasubramanian</em>

COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian

12 November 2020
<br>Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic</br><em> – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone </em>

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom ...

15 October 2020
<br>A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need</br><em> – by John Rex</em>

A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need ...

6 October 2020
<br>Why we need a new access model for antibiotics</br><em> – by Yann Ferrisse and Fernando Pascual Martinez</em>

Why we need a new access model for antibiotics – by Yann Ferrisse and Fernando Pascual Martinez

1 October 2020
<br>Moving from paper to action – The status of National AMR Action Plans in African countries</br><em> – by Mirfin Mpundu</em>

Moving from paper to action – The status of National AMR Action Plans in African countries – by Mirfin Mpundu

25 September 2020